Egalet Corp., of Wayne, Pa., said it closed its underwritten public offering of 16.66 million shares of its common stock and accompanying warrants to purchase up to 16.66 million shares, at a combined public offering price of $1.80 per share and accompanying warrant. The gross proceeds are expected to be approximately $30 million. The company anticipates using the net proceeds to support its commercial sales and marketing efforts for Arymo ER (morphine sulfate) extended-release tablets for oral use - CII, Sprix (ketorolac tromethamine) nasal spray and Oxaydo (oxycodone HCI, USP) tablets for oral use only CII, and for general corporate purposes. Cantor Fitzgerald & Co. acted as the sole book-running manager.